RIGL
Rigel Pharmaceuticals, Inc.NASDAQHealthcare$27.53+0.11%ClosedMarket Cap: $508.6M
As of 2026-04-06
Valuation
P/E (TTM)
1.39
PEG
0.00
P/B
1.26
P/S
1.72
EV/EBITDA
4.05
DCF Value
$-38.20
FCF Yield
15.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.3%
Operating Margin
42.6%
Net Margin
124.7%
ROE
240.8%
ROA
71.5%
ROIC
28.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $69.8M | 91.5% | $23.2M | $268.1M | $14.11 | — |
| FY 2025 | $294.3M | 93.3% | $125.5M | $367.0M | $19.48 | — |
| Q3 2025 | $69.5M | 93.2% | $28.4M | $27.9M | $1.46 | — |
| Q2 2025 | $101.7M | 95.6% | $61.1M | $59.6M | $3.28 | — |
| Q1 2025 | $53.3M | 91.7% | $12.8M | $11.4M | $0.63 | — |
| Q4 2024 | $57.6M | 89.9% | $16.7M | $14.3M | $0.80 | — |
| FY 2024 | $179.3M | 89.6% | $24.2M | $17.5M | $0.99 | — |
| Q3 2024 | $55.3M | 85.5% | $14.1M | $12.4M | $0.70 | — |
| Q2 2024 | $36.8M | 92.4% | $447.0K | $-1.0M | $-0.06 | — |
| Q1 2024 | $29.5M | 93.1% | $-7.0M | $-8.2M | $-0.47 | — |
| Q4 2023 | $35.8M | 89.4% | $2.0M | $737.0K | $0.04 | — |
| FY 2023 | $116.9M | 93.9% | $-20.5M | $-25.1M | $-1.44 | — |